|
🐜
|
EASL Clinical Practice Guidelines: management of chronic hepatitis B.
15 auth.
C.P.G.P.P. Marcellin,
G. Dusheiko,
F. Zoulim,
R. Esteban,
S. Hadziyannis,
P. Lampertico,
M. Manns,
D. Shouval,
C. Yurdaydın,
R. A. Craxi,
...
X. Forns,
D. Moradpour,
J. Pawlotsky,
J. Petersen,
H.W.F. Easl
|
10 |
2009 |
10
🐜
|
|
🐜
|
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.
15 auth.
B. Werle-Lapostolle,
S. Bowden,
S. Locarnini,
K. Wursthorn,
J. Petersen,
G. Lau,
C. Trépo,
P. Marcellin,
Z. Goodman,
W. Delaney,
...
S. Xiong,
C. Brosgart,
Shan-Shan Chen,
C. Gibbs,
F. Zoulim
|
9 |
2004 |
9
🐜
|
|
🐬
|
Control of cccDNA function in hepatitis B virus infection.
M. Levrero,
T. Pollicino,
J. Petersen,
L. Belloni,
G. Raimondo,
M. Dandri
|
9 |
2009 |
9
🐬
|
|
🐜
|
A global scientific strategy to cure hepatitis B.
51 auth.
P. Revill,
F. Chisari,
Joan M. Block,
M. Dandri,
A. Gehring,
Haitao Guo,
Jianming Hu,
A. Kramvis,
P. Lampertico,
H. Janssen,
M. Levrero,
Wenhui Li,
T. Liang,
S. Lim,
F. Lu,
...
M. Penicaud,
J. Tavis,
R. Thimme,
F. Zoulim,
P. Arbuthnot,
A. Boonstra,
K.‐M. Chang,
Per-Jei Chen,
D. Glebe,
L. Guidotti,
J. Fellay,
C. Ferrari,
L. Jansen,
Daryl T. Y. Lau,
Anna S.F. Lok,
M. Maini,
W. Mason,
G. Matthews,
D. Paraskevis,
J. Petersen,
B. Rehermann,
E. Shin,
A. Thompson,
F. van Bömmel,
Fu-sheng Wang,
Koichi Watashi,
Hung‐Chih Yang,
Zhenghong Yuan,
Man-Fung Yuen,
Tim Block,
V. Miller,
U. Protzer,
C. Bréchot,
S. Locarnini,
M. Peters,
R. Schinazi
|
8 |
2019 |
8
🐜
|
|
🐜
|
Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues
20 auth.
F. van Bömmel,
R. D. de Man,
H. Wedemeyer,
K. Deterding,
J. Petersen,
P. Buggisch,
A. Erhardt,
D. Hüppe,
K. Stein,
J. Trojan,
...
C. Sarrazin,
W. Böcher,
U. Spengler,
H. Wasmuth,
Jurrien G.P. Reinders,
B. Möller,
P. Rhode,
H. Feucht,
B. Wiedenmann,
T. Berg
|
8 |
2010 |
8
🐜
|
|
🐜
|
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
11 auth.
T. Volz,
L. Allweiss,
Mounira Ben MBarek,
M. Warlich,
A. Lohse,
J. Pollok,
...
A. Alexandrov,
S. Urban,
J. Petersen,
M. Lütgehetmann,
M. Dandri
|
8 |
2013 |
8
🐜
|
|
🐜
|
Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
19 auth.
W. R. Kim,
T. Berg,
T. Asselah,
R. Flisiak,
S. Fung,
S. Gordon,
H. Janssen,
P. Lampertico,
D. Lau,
J. Bornstein,
...
Raul Aguilar Schall,
Phillip Dinh,
L. Yee,
E. Martins,
S. Lim,
R. Loomba,
J. Petersen,
M. Buti,
P. Marcellin
|
8 |
2016 |
8
🐜
|
|
🐜
|
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
15 auth.
T. Welzel,
J. Petersen,
K. Herzer,
P. Ferenci,
M. Gschwantler,
H. Wedemeyer,
T. Berg,
U. Spengler,
O. Weiland,
M. van der Valk,
...
J. Rockstroh,
M. Peck‐Radosavljevic,
Yue Zhao,
M. Jiménez-Expósito,
S. Zeuzem
|
7 |
2016 |
7
🐜
|
|
🐢
|
Discontinuation of oral antivirals in chronic hepatitis B: A systematic review
7 auth.
G. Papatheodoridis,
I. Vlachogiannakos,
E. Cholongitas,
K. Wursthorn,
Christos Thomadakis,
G. Touloumi,
...
J. Petersen
|
7 |
2016 |
7
🐢
|
|
🐢
|
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
18 auth.
T. Berg,
K. Simon,
S. Mauss,
E. Schott,
R. Heyne,
D. Klass,
C. Eisenbach,
T. Welzel,
R. Zachoval,
G. Felten,
...
J. Schulze-Zur-Wiesch,
M. Cornberg,
M. L. Op den Brouw,
B. Jump,
H. Reiser,
L. Gallo,
T. Warger,
J. Petersen
|
7 |
2017 |
7
🐢
|
|
🐜
|
Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation
12 auth.
A. Lohse,
Rudolf Mancke,
M. Lütgehetmann,
Lida V. Mancke,
T. Volz,
M. Helbig,
...
L. Allweiss,
T. Bornscheuer,
J. Pollok,
J. Petersen,
S. Urban,
M. Dandri
|
7 |
2012 |
7
🐜
|
|
🐜
|
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians
22 auth.
P. Arends,
M. Sonneveld,
R. Zoutendijk,
I. Carey,
A. Brown,
M. Fasano,
D. Mutimer,
K. Deterding,
J. Reijnders,
Y. Oo,
...
J. Petersen,
F. van Bömmel,
R. D. de Knegt,
T. Santantonio,
T. Berg,
T. Welzel,
H. Wedemeyer,
M. Buti,
P. Pradat,
F. Zoulim,
B. Hansen,
H. Janssen
|
7 |
2014 |
7
🐜
|
